Press Releases
Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents.
July 7, 2010 - PDF Version
Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines.
March 16, 2010 - PDF Version
Scientists Rediscover Gene Target for Cancer Therapy
December 15, 2009 - PDF Version
Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved
October 14, 2009 - PDF Version
Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine.
October 12, 2009 - PDF Version
Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
June 22, 2009 - PDF Version
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
June 17, 2009 - PDF Version
The World's Smallest Hero! Rexin-G, Targeted Therapy for Metastatic Cancers.
June 9, 2009 - PDF Version
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
May 18, 2009 - PDF Version
Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial
(Proceedings of ASCO GI Symposium 2009)
January 20, 2009 - PDF Version
Epeius Biotechnologies Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
December 16, 2008 - PDF Version
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase ii Studies
November 21, 2008 - PDF Version
Rexin-G Returns to the Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan.
October 29, 2008 - PDF Version
Targeting Metastatic Cancer From The Inside: Epeius Biotech Reveals A New Generation Of Tools For Medical Gene Delivery
October 6, 2008 - PDF Version
Epeius Biotechnologies’ Lead Product, Rexin-G For Metastatic Cancer, Aptly Highlighted By National Cancer Institute Journal
September 15, 2008 - PDF Version
FDA Grants Epeius Biotechnologies’ Rexin-G A Third Orphan Drug Designation, This Time For The Treatment Of Soft Tissue Sarcomas
July 09, 2008 - PDF Version
Epeius’ Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation For The Treatment Of Osteosarcoma
July 08, 2008 - PDF Version
Phase I/II Study Of Targeted Gene Delivery In Vivo—Intravenous Infusions Of Rexin-G—Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity In Patients With Progressive Chemo-Resistant Bone And Soft Tissue Sarcoma (ASCO 2008)
May 29, 2008 - PDF Version
TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G followed by Reximmune-C induce tumor necrosis and recruitment of tumor infiltrating lymphocytes in cancerous lesions (ASCO 2008)
May 27, 2008 PDF Version
Targeted Gene Delivery In Vivo: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity In Chemo-Resistant Metastatic Breast Cancer (Asco 2008)
May 22, 2008 PDF Version
Asco 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity In Metastatic Pancreatic Cancer
May 19, 2008 PDF Version
Interim Analysis Of Phase I/Ii Study Of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity In Metastatic Pancreatic Cancer; Second Phase Opens With Higher Dose Regimens
April 21, 2008 PDF Version
Epeius Biotechnologies awarded U.S. patent for targeted injectable gene delivery In Vivo
March 25, 2008 PDF Version
